# EDGAR Filing Document

**Accession Number:** 0002093136
**File Stem:** 0000912282-25-001148
**Filing Date:** 2025-10
**Character Count:** 9664
**Document Hash:** 8540db3da250f10f95c3dc56bebddba1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000912282-25-001148.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0000912282-25-001148

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Flora Growth Corp.
- **CENTRAL INDEX KEY:** 0001790169
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93855
- **FILM NUMBER:** 251417579

**BUSINESS ADDRESS:**
- **STREET 1:** 3230 W. COMMERCIAL BOULEVARD
- **STREET 2:** SUITE 180
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33309
- **BUSINESS PHONE:** 416-861-2267

**MAIL ADDRESS:**
- **STREET 1:** 3230 W. COMMERCIAL BOULEVARD
- **STREET 2:** SUITE 180
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33309
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Heinrich Michael
- **CENTRAL INDEX KEY:** 0002093136

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O FLORA GROWTH CORP.
- **STREET 2:** 3230 W. COMMERCIAL BLVD., SUITE 180
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33309

## Exhibit 99.1

EXHIBIT 1.01

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: October 26, 2025

---

| |
|:---|
| &nbsp;&nbsp; **Zero Gravity Labs Inc.**  |
| &nbsp;&nbsp; By: /s/ Michael Heinrich  |
| &nbsp;&nbsp; Name: Michael Heinrich <br> Title: Chief Executive Officer  |
| &nbsp;&nbsp; <u>/s/ Michael Heinrich</u>_________________________  |
| &nbsp;&nbsp; Michael Heinrich  |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Flora Growth Corp.**

*(Name of Issuer)*

**Common Shares, no par value**

*(Title of Class of Securities)*

**339764102**

*(CUSIP Number)*

**Richard Raymer**<br>Dorsey & Whitney LLP<br>66 Wellington St. W., Suite 3400<br>Toronto A6 M5K 1E6<br>(416) 367-7370

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **339764102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Heinrich Michael** | Name of reporting person<br>**Heinrich Michael** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4902220.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4902220.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4902220.00** | Aggregate amount beneficially owned by each reporting person<br>**4902220.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**87.0%** | Percent of class represented by amount in Row (11)<br>**87.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **339764102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Zero Gravity Labs Inc.** | Name of reporting person<br>**Zero Gravity Labs Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4902220.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4902220.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4902220.00** | Aggregate amount beneficially owned by each reporting person<br>**4902220.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**87.0%** | Percent of class represented by amount in Row (11)<br>**87.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value

**(b) Name of Issuer:**
Flora Growth Corp.

**(c) Address of Issuer's Principal Executive Offices:**
3230 W. Commercial Blvd., Suite 180, Fort Lauderdale, FL, 33132

**Item 4. Purpose of Transaction**

On September 20, 2025, the Reporting Person was appointed as a director and as the Chairman of the Board of the Issuer.  On October 22, 2025, the Issuer's shareholders approved the issuance of a convertible promissory note dated October 23, 2025 (the "Note") to 0G.  The principal amount of the Note, having a U.S. dollar value of $150,000,000, may be converted at the option of the OG into common shares of the Issuer at a conversion price of US$33.34 per share.  The total number of Issuer common shares underlying the principal amount of the Note are 4,499,100.  The total number of common shares of the Issuer underlying the interest on the Note, projected through September 30, 2026 are 403,120.

**Item 5. Interest in Securities of the Issuer**

**(a)**
4,902,000 common shares; 87.0%

**(b)**
i) Total sole voting and dispositive authority:  4,902,220; total shared voting and dispositive authority:  0; Total Shares:  4,902,220; Percentage -  87.0%ii)  Total sole voting and dispositive authority:  0; total shared voting and dispositive authority:  4,902,220; Total Shares:  4,902,220; Percentage  - 87.0%

**(c)**
On September 20, 2025, the Reporting Person was appointed as a director and as the Chairman of the Board of the Issuer.  On September 19, 2025, the Issuer entered into a loan agreement with 0G whereby the Issuer agreed to issue to 0G a total of 1,786,432 exercisable for common shares of the Issuer at an exercise price of $0.01 per share.  The warrants were cancelled and replaced with the Note on October 23, 2025, following shareholder approval.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Form of Convertible Note dated September 22, 2025, between the Issuer and 0G

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Heinrich Michael

**Signature:** Michael Heinrich

**Name/Title:** Reporting Person

**Date:** 10/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Zero Gravity Labs Inc.

**Signature:** Michael Heinrich

**Name/Title:** Director of Zero Gravity Labs Inc.

**Date:** 10/26/2025